Corporate Presentation November 4, 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte's carrier-sparing platform and vaccine candidates, including breadth of coverage and the ability to deliver potentially better immune responses, a potentially best-in-class pneumococcal conjugate vaccine (PCV) ...

Core Viewpoint - Dividend stocks provide high yields and growth catalysts that can support payouts for decades, making them attractive for passive income investors [1][2]. Group 1: Dividend Stocks Overview - Building passive income through dividend-paying stocks allows investors to secure financial freedom by generating regular cash distributions [2]. - Dividend stocks combine income with potential long-term capital appreciation, offering protection against inflation through rising distributions [3]. Group 2: Company-Specific Insights - Philip Morris International offers a 3.6% yield with an 80% payout ratio, supported by its transformation towards smoke-free products, which generated 39% of 2024 revenue [6][7]. - Pfizer provides a 7.14% yield at 7.7 times forward earnings, with projected revenue of $61 billion to $64 billion in 2025, driven by various growth products and an acquisition of Metsera for up to $7.3 billion [8][9]. Group 3: Investment Considerations - Philip Morris trades at a discount with a forward earnings ratio of 19.4 compared to 22 for the S&P 500, while maintaining a credible path to smoke-free growth [7]. - Pfizer's high payout ratio of 90% presents execution risks, but management's commitment to dividends and lower expense guidance suggest a compelling risk-reward balance [9][11]. Group 4: Passive Income Strategy - Both Philip Morris and Pfizer offer different paths to passive income, with a combined yield of approximately 5.4%, significantly higher than the S&P 500 average [10]. - Sustainable yields backed by strong business fundamentals are crucial for passive income investing, with both companies demonstrating potential despite facing regulatory challenges [11].

Company Overview - Vaxcyte (PCVX) is a clinical-stage biotech company focused on developing vaccines for bacterial infectious diseases [1] - The company's shares have experienced a significant decline of 56% in the past month due to mixed results from a phase II study on its pneumococcal conjugate vaccine (PCV) [1][3] Stock Performance - Year-to-date, Vaxcyte's shares have plummeted over 62%, significantly underperforming the industry, which has seen an 8% decline [3] - The stock is trading below its 50 and 200-day moving averages, indicating weak market sentiment [3] Vaccine Study Results - Vaxcyte's recent mid-stage study evaluated its 24-valent PCV VAX-24 against Pfizer's Prevnar 20, which is approved for preventing invasive pneumococcal disease caused by 20 serotypes [6] - The mid-dose of VAX-24 met non-inferiority criteria for seroconversion and showed robust immune responses, but did not meet the criteria for four of the 24 serotypes compared to Prevnar 20, contributing to the stock's decline [7] - VAX-24 was well-tolerated and demonstrated a safety profile similar to Prevnar 20, with strong markers for protection against invasive pneumococcal disease [8] Future Development Plans - Based on the study results, Vaxcyte plans to advance the mid-dose formulation of VAX-24 into late-stage development [9] - The company is also conducting a mid-stage study on its investigational 31-valent PCV vaccine VAX-31, with top-line results expected in mid-2026, and plans to start a phase III study in infants with either VAX-24 or VAX-31 [10] Industry Context - The broader biotech and drug sector is facing challenges, including the resignation of a senior FDA official, raising concerns about the agency's ability to maintain innovation and regulatory clarity [2]

Group 1: Merck's Capvaxive Approval - The European Commission has approved Merck's 21-valent pneumococcal conjugate vaccine, Capvaxive, for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in individuals aged 18 years and above [1][2] - Capvaxive targets serotypes responsible for approximately 84% of all invasive pneumococcal diseases in older adults in the United States, including eight serotypes not covered by currently licensed vaccines [2][3] - The approval was based on safety and immunogenicity data from the STRIDE clinical program, including phase III studies comparing Capvaxive to PCV20 [3][4] Group 2: Market Context and Competitors - Year to date, Merck's shares have decreased by 11.5%, while the industry has seen a rise of 4.4% [2] - Pfizer is a key competitor in the pneumococcal conjugate vaccine space, marketing Prevnar 20 and Prevnar 13, which generated $6.4 billion in combined sales in 2024 [5][7] - Sanofi has expanded its collaboration with SK bioscience to develop next-generation pneumococcal conjugate vaccines, including a 21-valent PCV for pediatric populations [8][9] - Vaxcyte is developing a 31-valent PCV, VAX-31, which is in mid-to-late-stage studies for preventing invasive pneumococcal disease in both pediatric and adult populations [10]